• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I 型干扰素通过 Tie2 依赖性途径诱导红斑狼疮患者血管内皮失稳。

Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.

机构信息

Rheumatology and Immune-mediated Diseases Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain.

Rheumatology Department, University Hospital of Vigo, Vigo, Spain.

出版信息

Front Immunol. 2023 Dec 14;14:1277267. doi: 10.3389/fimmu.2023.1277267. eCollection 2023.

DOI:10.3389/fimmu.2023.1277267
PMID:38162654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10756137/
Abstract

Endothelial cell (EC) dysfunction is a hallmark of Systemic Lupus Erythematosus (SLE) and Tie2 is a receptor essential for vascular stability. Inflammatory processes promote inhibition of Tie2 homeostatic activation, driving vascular dysfunction. In this work we determined whether type I Interferons (IFN) induce Tie2 signalling-mediated endothelial dysfunction in patients with SLE. Serum levels of Angiopoietin (Ang)-1, Ang-2 and soluble (s)Tie1 in patients with SLE and healthy controls were measured by ELISA. Monocytes from patients with SLE and Human Umbilical Vein EC (HUVEC) were stimulated with IFN-α, IFN-β (1000 I.U.) or SLE serum (20%). mRNA and protein expression, phosphorylation and translocation were determined by quantitative PCR, ELISA, Western Blot, flow cytometry and confocal microscopy. Viability and angiogenic capacity were determined by calcein and tube formation assays. We found that sTie1 and Ang-2 serum levels were increased and Ang-1 decreased in patients with SLE and were associated with clinical characteristics. Type I IFN significantly decreased Ang-1 and increased Ang-2 in monocytes from patients with SLE. Type I IFN increased sTie1 and Ang-2 secretion and reduced Tie2 activation in HUVEC. Functionally, type I IFN significantly reduced EC viability and impaired angiogenesis in a Tie2 signalling-dependent manner. Finally, SLE serum increased Ang-2 and sTie1 secretion and significantly decreased tube formation. Importantly, Tie1 and IFNAR1 knockdown reversed these effects in tube formation. Overall, type I IFN play an important role in the stability of EC by inhibiting Tie2 signalling, suggesting that these processes may be implicated in the cardiovascular events observed in patients with SLE.

摘要

内皮细胞 (EC) 功能障碍是系统性红斑狼疮 (SLE) 的标志,而 Tie2 是血管稳定性所必需的受体。炎症过程促进 Tie2 稳态激活的抑制,导致血管功能障碍。在这项工作中,我们确定了 I 型干扰素 (IFN) 是否会诱导 SLE 患者的 Tie2 信号介导的内皮功能障碍。通过 ELISA 测定 SLE 患者和健康对照者血清中血管生成素 (Ang)-1、Ang-2 和可溶性 (s)Tie1 的水平。用 IFN-α、IFN-β (1000 I.U.) 或 SLE 血清 (20%) 刺激 SLE 患者的单核细胞和人脐静脉内皮细胞 (HUVEC)。通过定量 PCR、ELISA、Western blot、流式细胞术和共聚焦显微镜测定 mRNA 和蛋白表达、磷酸化和转位。通过钙黄绿素和管形成测定法测定细胞活力和血管生成能力。我们发现,SLE 患者的 sTie1 和 Ang-2 血清水平升高,Ang-1 降低,且与临床特征相关。I 型 IFN 显著降低了 SLE 患者单核细胞中的 Ang-1 并增加了 Ang-2。I 型 IFN 增加了 HUVEC 中 sTie1 和 Ang-2 的分泌,并降低了 Tie2 的激活。功能上,I 型 IFN 显著降低了 EC 的活力,并以 Tie2 信号依赖性方式损害了血管生成。最后,SLE 血清增加了 Ang-2 和 sTie1 的分泌,并显著减少了管形成。重要的是,Tie1 和 IFNAR1 的敲低逆转了管形成中的这些作用。总之,I 型 IFN 通过抑制 Tie2 信号在 EC 的稳定性中发挥重要作用,这表明这些过程可能与 SLE 患者观察到的心血管事件有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/16727cf27cf7/fimmu-14-1277267-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/a23f2bdbc859/fimmu-14-1277267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/e9f23d4b9165/fimmu-14-1277267-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/e9ab71cec35f/fimmu-14-1277267-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/ee8db60c0c57/fimmu-14-1277267-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/c7ccbb7a9ebd/fimmu-14-1277267-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/16727cf27cf7/fimmu-14-1277267-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/a23f2bdbc859/fimmu-14-1277267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/e9f23d4b9165/fimmu-14-1277267-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/e9ab71cec35f/fimmu-14-1277267-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/ee8db60c0c57/fimmu-14-1277267-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/c7ccbb7a9ebd/fimmu-14-1277267-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f51/10756137/16727cf27cf7/fimmu-14-1277267-g006.jpg

相似文献

1
Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.I 型干扰素通过 Tie2 依赖性途径诱导红斑狼疮患者血管内皮失稳。
Front Immunol. 2023 Dec 14;14:1277267. doi: 10.3389/fimmu.2023.1277267. eCollection 2023.
2
Tie1 controls angiopoietin function in vascular remodeling and inflammation.Tie1在血管重塑和炎症中控制血管生成素的功能。
J Clin Invest. 2016 Sep 1;126(9):3495-510. doi: 10.1172/JCI84923. Epub 2016 Aug 22.
3
The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.Tie2受体拮抗剂血管生成素2促进系统性红斑狼疮中的血管炎症。
Ann Rheum Dis. 2009 Oct;68(10):1638-43. doi: 10.1136/ard.2008.094664. Epub 2008 Oct 17.
4
Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells.酪氨酸磷酸酶β调节人内皮细胞中的血管生成素-Tie2信号通路。
Angiogenesis. 2009;12(1):25-33. doi: 10.1007/s10456-008-9126-0. Epub 2009 Jan 1.
5
Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells.Tie1 调节血管生成素-2 对人淋巴管内皮细胞的 Tie2 激动作用。
Biochem Biophys Res Commun. 2012 Mar 9;419(2):281-6. doi: 10.1016/j.bbrc.2012.02.009. Epub 2012 Feb 10.
6
Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.青蒿琥酯抑制系统性红斑狼疮患者中I型干扰素诱导的巨噬细胞移动抑制因子的产生。
Lupus. 2017 Jan;26(1):62-72. doi: 10.1177/0961203316651738. Epub 2016 May 26.
7
The molecular balance between receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF and TNFα and regulates angiopoietin signalling.受体酪氨酸激酶 Tie1 和 Tie2 之间的分子平衡受 VEGF 和 TNFα 的动态调控,并调节血管生成素信号通路。
PLoS One. 2012;7(1):e29319. doi: 10.1371/journal.pone.0029319. Epub 2012 Jan 3.
8
Tie2 as a novel key factor of microangiopathy in systemic sclerosis.Tie2作为系统性硬化症微血管病变的一个新的关键因素。
Arthritis Res Ther. 2017 May 25;19(1):105. doi: 10.1186/s13075-017-1304-2.
9
Anti-angiogenic properties of a sulindac analogue.舒林酸类似物的抗血管生成特性
Br J Pharmacol. 2007 Dec;152(8):1207-14. doi: 10.1038/sj.bjp.0707534. Epub 2007 Oct 29.
10
Long noncoding TUG1 promotes angiogenesis of HUVECs in PE via regulating the miR-29a-3p/VEGFA and Ang2/Tie2 pathways.长链非编码 TUG1 通过调控 miR-29a-3p/VEGFA 和 Ang2/Tie2 通路促进 PE 中 HUVEC 的血管生成。
Microvasc Res. 2022 Jan;139:104231. doi: 10.1016/j.mvr.2021.104231. Epub 2021 Aug 2.

引用本文的文献

1
Macrophages Unmasked: Their Pivotal Role in Driving Atherosclerosis in Systemic Lupus Erythematosus.巨噬细胞被揭开面纱:它们在系统性红斑狼疮引发动脉粥样硬化中的关键作用。
Clin Rev Allergy Immunol. 2025 Feb 7;68(1):10. doi: 10.1007/s12016-025-09025-6.
2
Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus.新型内皮祖细胞群体作为全身性红斑狼疮损伤和缓解的生物标志物。
Arthritis Res Ther. 2024 Sep 28;26(1):170. doi: 10.1186/s13075-024-03397-4.

本文引用的文献

1
Emerging concepts of type I interferons in SLE pathogenesis and therapy.I 型干扰素在系统性红斑狼疮发病机制和治疗中的新观点。
Nat Rev Rheumatol. 2022 Oct;18(10):575-590. doi: 10.1038/s41584-022-00826-z. Epub 2022 Sep 12.
2
Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.系统性红斑狼疮和系统性硬化症中的内皮功能障碍:不同微血管疾病的共同触发因素
Front Med (Lausanne). 2022 Apr 8;9:849086. doi: 10.3389/fmed.2022.849086. eCollection 2022.
3
Inside the Joint of Inflammatory Arthritis Patients: Handling and Processing of Synovial Tissue Biopsies for High Throughput Analysis.
炎症性关节炎患者关节内部:用于高通量分析的滑膜组织活检样本的处理与加工
Front Med (Lausanne). 2022 Mar 14;9:830998. doi: 10.3389/fmed.2022.830998. eCollection 2022.
4
The multifaceted impact of complement on atherosclerosis.补体对动脉粥样硬化的多方面影响。
Atherosclerosis. 2022 Jun;351:29-40. doi: 10.1016/j.atherosclerosis.2022.03.014. Epub 2022 Mar 17.
5
Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.系统性红斑狼疮中的心血管疾病风险和发病机制。
Semin Immunopathol. 2022 May;44(3):309-324. doi: 10.1007/s00281-022-00922-y. Epub 2022 Mar 30.
6
Signaling pathways and targeted therapy for myocardial infarction.心肌梗死的信号通路和靶向治疗。
Signal Transduct Target Ther. 2022 Mar 10;7(1):78. doi: 10.1038/s41392-022-00925-z.
7
2021 DORIS definition of remission in SLE: final recommendations from an international task force.2021 年 DORIS 系统性红斑狼疮缓解定义:国际工作组的最终建议。
Lupus Sci Med. 2021 Nov;8(1). doi: 10.1136/lupus-2021-000538.
8
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.系统性红斑狼疮和其他自身免疫性疾病中干扰素通路的发病机制、分子机制及治疗潜力。
Int J Mol Sci. 2021 Oct 19;22(20):11286. doi: 10.3390/ijms222011286.
9
Anifrolumab: First Approval.阿尼鲁单抗:首次批准。
Drugs. 2021 Oct;81(15):1795-1802. doi: 10.1007/s40265-021-01604-z.
10
Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE.红细胞线粒体滞留引发人类 SLE 中髓系依赖性 I 型干扰素。
Cell. 2021 Aug 19;184(17):4464-4479.e19. doi: 10.1016/j.cell.2021.07.021. Epub 2021 Aug 11.